Canadian diagnostics developer Breathe BioMedical sets terms for $8 million US IPO
I'm PortAI, I can summarize articles.
Canadian diagnostics developer Breathe BioMedical is planning an $8 million US IPO. The company is focused on developing a breath test for breast cancer as an adjunctive test to mammography screening. Breathe BioMedical aims to complete verification and validation studies by 2025 and a pivotal trial in 2026 to support a marketing authorization application in the US in 2027. The company was founded in 2005 and plans to list on the Nasdaq under the symbol BRTH.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: RenaissanceCapital The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments